- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03443674
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies
A Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Peritoneal Malignancies
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
Orange, New South Wales, Australia, 2800
- Orange Health Service
-
Wollongong, New South Wales, Australia, 2500
- Southern Medical Day Care Centre
-
-
Queensland
-
Tugun, Queensland, Australia, 4224
- John Flynn Private Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
- Flinders Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed peritoneal malignancies after failure or refusal of all approved therapies, and no better option available in the Investigator's opinion.
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 2 (Patients with ECOG score of 3 might be allowed to enter this trial per Investigator's judgment)
- Life expectancy of at least 8 weeks
- Age ≥18 years
- Body mass index ≥17.0 kg/m2
Adequate hematological function, defined as:
- Platelet count ≥ 75,000/μL
- Prothrombin time and activated partial thromboplastin time ≤1.5 times the upper limit of normal (ULN)
- Absolute neutrophil count ≥1,500/μL
- Hemoglobin ≥8 g/dL (transfusion and erythropoietic agents are allowed. In case there is existence of active bleeding or other persistent condition of either increased destruction or impaired production of erythrocytes which may require repeated transfusion or erythropoietic treatment, the eligibility must be discussed with the Sponsor on a case-by-case basis prior to randomization)
- Adequate renal function, defined as serum creatinine ≤2.0 times ULN and creatinine clearance >45 mL/minute
Adequate liver function, defined as:
- Aspartate aminotransferase and alanine aminotransferase ≤3 times ULN for patients without liver metastases, or ≤5 times ULN in the presence of liver metastases
- Bilirubin ≤1.5 times ULN, unless patient has known Gilbert's syndrome
- Female patients of childbearing potential (excluding women who have undergone surgical sterilization or menopause. Menopause is defined as the status where no menstrual periods continue for 1 year or more without any other medical reasons), are eligible if they have negative serum pregnancy testing within 7 days prior to first dosing and are willing to use an effective method of birth control/contraception to prevent pregnancy until 6 months after discontinuation of the SCB-313.
Both men and women of reproductive potential must agree to use effective contraception during the study and for 6 months after discontinuation of the SCB-313.
Note: Contraceptive methods that are considered highly effective are, for example, total abstinence, an intrauterine device, a double barrier method (such as condom plus diaphragm with spermicide), a contraceptive implant, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices, or injections with prolonged release), or have a vasectomized partner with confirmed azoospermia.
Exclusion Criteria:
- Acute or chronic infection (such as tuberculosis) requiring antiviral or intravenous (IV) antibiotics within 2 weeks prior to enrollment.
- Symptoms or signs (including laboratory tests) of clinically significant concomitant hematologic, cardiovascular, pulmonary, hepatic, renal, pancreatic, or endocrine diseases.
- Residual adverse events (AEs) > Grade 2 from previous treatment.
- Evidence or suspicion of relevant psychiatric impairment including alcohol or recreational drug abuse.
- Myocardial infarction within 6 months prior to treatment, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication, and/or long QT syndrome or QT/QTc interval >450 msec at baseline.
- Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg confirmed upon repeated measures.
- Left ventricular ejection fraction <40% as determined by echocardiography performed at screening or within 90 days prior to enrollment.
- Prior anti-tumor therapy (chemotherapy) within 2 weeks, hormone therapy or palliative extra-abdominal radiotherapy within at least 1 week, or small-molecule targeted therapy within 5 half-lives prior to enrollment. Prior therapy with monoclonal antibody should be stopped after Investigator's judgement making sure delayed side effects will not interfere with the dose limiting toxicity (DLT) evaluation period after SCB-313 therapy.
- Major surgery within 4 weeks prior to enrollment.
- Patient with ileus within 30 days prior to screening.
- Positive serology test for human immunodeficiency virus Type 1 and 2 or known history of other immunodeficiency disease.
- Live vaccine within 2 weeks prior to enrollment.
- Scheduled participation in another clinical study involving an investigational product or device during the course of this study.
- Previous treatment with a TRAIL-based therapy or death receptor (DR) 4/5 agonist therapy.
- Known or suspected hypersensitivity to any component of the SCB-313.
- Any further condition which, according to the Investigator, may result in undue risk of the patient by participating in the present study.
- Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SCB-313
Dose escalation cohorts--10mg, 20mg, 40mg, 80mg, 160mg.
For each cohort: administered twice weekly (eg.. Monday and Thursday or Tuesday and Friday) for 2 weeks (Days 1, 4, 8, and 11) by IP bolus injection.
|
Lyophilized powder in a single-use vial
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability: Occurrence of serious adverse events (SAEs) and/or TEAEs
Time Frame: Up to 41 days after start of treatment
|
Regardless of causality or relationship to SCB-313 graded using National Cancer Institute Common Terminology Criteria for Adverse Events Version.4.03 (NCI CTCAE v4.03).
|
Up to 41 days after start of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity: Occurrence of binding and neutralizing anti-SCB-313 antibodies
Time Frame: Up to 41 days after start of treatment
|
Occurrence of binding and neutralizing anti-SCB-313 antibodies
|
Up to 41 days after start of treatment
|
Pharmacokinetics (Cmax)
Time Frame: Up to 12 days after start of treatment
|
Maximum serum concentration
|
Up to 12 days after start of treatment
|
Pharmacokinetics (Cmax/D)
Time Frame: Up to 12 days after start of treatment
|
Dose-normalized Cmax of SCB-313
|
Up to 12 days after start of treatment
|
Pharmacokinetics (tmax)
Time Frame: Up to 12 days after start of treatment
|
Time to Cmax of SCB-313
|
Up to 12 days after start of treatment
|
Pharmacokinetics ([AUC]0-24)
Time Frame: Up to 12 days after start of treatment
|
Area under SCB-313 concentration time curve from zero to 24 hours
|
Up to 12 days after start of treatment
|
Pharmacokinetics (AUC0-24/D)
Time Frame: Up to 12 days after start of treatment
|
Dose-normalized AUC0-24 of SCB-313
|
Up to 12 days after start of treatment
|
Pharmacokinetics ((AUC0-last))
Time Frame: Up to 12 days after start of treatment
|
Area under curve from time 0 on Day 1 to the last quantifiable concentration time point
|
Up to 12 days after start of treatment
|
Pharmacokinetics (Ctrough)
Time Frame: Up to 12 days after start of treatment
|
Trough concentration of SCB-313 at each predose and at 24 hours after the last dose
|
Up to 12 days after start of treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CEA
Time Frame: Up to 6 months after start of treatment
|
Changes in serum tumor marker(CEA)
|
Up to 6 months after start of treatment
|
Caspase-cleaved cytokeratin 18 (CK-18)
Time Frame: Up to 21 days after start of treatment
|
Changes in serum PD biomarkers
|
Up to 21 days after start of treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLO-SCB-313-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peritoneal Malignancies
-
University of California, San DiegoCompleted
-
The University of Hong KongRecruitingPeritoneal MetastasesHong Kong
-
Yonsei UniversityCompletedPeritoneal Surface MalignanciesKorea, Republic of
-
Lumicell, Inc.RecruitingPeritoneal MetastasesUnited States
-
Hospices Civils de LyonUnknownPseudomyxoma Peritonei | Peritoneal Mesothelioma | Desmoplastic Small Round Cell Tumor | Rare Peritoneal Surface Malignancies | Psammocarcinoma | Primary Peritoneal Serous Carcinoma | Diffuse Peritoneal Leiomyomatosis | Appendiceal Mucinous NeoplasmsFrance
-
David BartlettNational Cancer Institute (NCI)CompletedPeritoneal Carcinomatosis | Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface | Malignant Peritoneal MesotheliomaUnited States
-
Dan Blazer III, M.D.CompletedStage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be Completely ResectedUnited States
-
Wuhan UniversityCompletedPostoperative Cognitive DysfunctionChina
-
Amsterdam UMC, location VUmcCompletedColorectum Advanced Malignancies | Breast Advanced Malignancies | Prostate Advanced MalignanciesNetherlands
-
Albert Einstein College of MedicineCompletedGastric Cancer | Colorectal Cancer | Pseudomyxoma Peritonei | Peritoneal Carcinomatosis | Peritoneal Mesothelioma | Appendiceal CancerUnited States
Clinical Trials on SCB-313
-
Sichuan Clover Biopharmaceuticals, Inc.CompletedMalignant Pleural EffusionChina
-
Sichuan Clover Biopharmaceuticals, Inc.Completed
-
Sichuan Clover Biopharmaceuticals, Inc.TerminatedPeritoneal CarcinomatosisChina
-
Clover Biopharmaceuticals AUS Pty LtdCompletedMalignant Pleural EffusionsAustralia
-
Servier Deutschland GmbHiOMEDICO AGCompleted
-
BayerCompletedAtopic DermatitisFrance, Czechia, Italy, Poland, United States, Germany, United Kingdom
-
Phoenicis TherapeuticsTerminatedEpidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, DominantUnited States, Spain, France
-
Otonomy, Inc.CompletedSubjective TinnitusUnited States, United Kingdom, Germany, Poland
-
Otonomy, Inc.Completed
-
Wyeth is now a wholly owned subsidiary of PfizerSolvay PharmaceuticalsTerminated